The effect of add-on beta2 agonist in paitents with COPD treatd with tiotropium

The effect of add-on beta2 agonist in paitents with COPD treatd with tiotropium - The effect of add-on beta2 agonist in paitents with COPD treatd with tiotropium

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003401

Enrollment

100

Registered

2010-03-29

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

inhaled short acting beta2 agonist inhaled long acting beta2 agonist

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients who are diagnosed by the criteria of GOLD guideline, and treated with tiotropium. 1) FEV1/FVC <0.7 30%<=%FEV1<80% 2) suffer from dyspnea 3) over 40years old 4) have a smoking history 5) does not change other treatment

Exclusion criteria

Exclusion criteria: 1) bronchial asthma 2) needs systemic steroids 3) under long term oxygen therapy 4) drug aleergy 5) who are not suitable for beta2 inhalation (hyperthyroidism, hypertension,and so on) 6) glaucoma 7) miction imparement 8) pregnacy

Design outcomes

Primary

Measure	Time frame
Dyspnae scale, QoL	—

Secondary

Measure	Time frame
the frequency of on demand use of bronchodilators, the frequency of exacerbation, lung functions	—

Countries

Japan

Contacts

Public ContactShigeo Muro

Kyoto univeristy, faculty of medicine respiratory medicine

smuro@kuhp.kyoto-.ac.jp075-751-3830

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026